Business

Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday 17 September 2025

Oslo, Norway, 10 September 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces an Investor Science and Strategy Forum to be held in Oslo on Wednesday 17 September 2025 at 11:30am CET. Attendance by registration only. The format will be a panel discussion and open questions and answers (Q&A). The panel will include: Dr. Namir Hassan, CEO, Zelluna ASA, Moderator Prof. Bent Jakobsen, P

articleZelluna AsaSeptember 10, 20252/company/zelluna-asa/news/zelluna-announces-investor-forum-on-science-and-strategy-to-be-held-on-wednesday-17-september-2025
Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday 17 September 2025

About this update from Zelluna Asa

[{"type":"image","alt":"Zelluna ASA","displaySize":"","headline":null,"caption":"Zelluna ASA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C3Qdgv86SfCXtr_6x5fSRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69","width":300,"height":106}},"lazy":false},{"type":"text","content":"Oslo, Norway, 10 September 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces an Investor Science and Strategy Forum to be held in Oslo on Wednesday 17 September 2025 at 11:30am CET.","length":298,"tagName":"p"},{"type":"text","content":"Attendance by registration only.","length":32,"tagName":"p"},{"type":"text","content":"The format will be a panel discussion and open questions and answers (Q&A).","length":79,"tagName":"p"},{"type":"text","content":"The panel will include:","length":23,"tagName":"p"},{"type":"text","content":"Dr. Namir Hassan, CEO, Zelluna ASA, Moderator","length":45,"tagName":"p"},{"type":"text","content":"Prof. Bent Jakobsen, Pioneer of T Cell Receptor (TCR) therapy for cancer; former founder of two public TCR based companies including Immunocore. Zelluna ASA Board Member.","length":170,"tagName":"p"},{"type":"text","content":"Prof Fiona Thistlethwaite, Medical Oncology Consultant within the Experimental Cancer Medicines Team (ECMT), Clinical Lead for the Advanced Immunotherapy and Cell Therapy (AICT) Team, The Christie, UK","length":200,"tagName":"p"},{"type":"text","content":"Details of the event are as follows:","length":36,"tagName":"p"},{"type":"text","content":"Date: Wednesday 17 September 2025.","length":34,"tagName":"p"},{"type":"text","content":"Time: 11:30 – 13:00 CET, Lunch served.","length":38,"tagName":"p"},{"type":"text","content":"Venue: Meeting Room 4, Hotel Continental, Stortingsgata 24/26, Oslo.","length":68,"tagName":"p"},{"type":"text","content":"Format: Panel discussion and open Q&A 12:00 – 13:00 CET.","length":60,"tagName":"p"},{"type":"text","content":"Attendance is by registration only and spaces are limited. ","length":58,"tagName":"p"},{"type":"text","conten...

More updates from Zelluna Asa

Zelluna ASApanel discussionT Cell ReceptorNamir HassanExperimental Cancer Medicines Teamtreatment of cancerTCR-NKProf Fiona ThistlethwaiteNatural KillerZelluna ASA Board Member